Pacific Biosciences
PACB
90 hedge funds and large institutions have $156M invested in Pacific Biosciences in 2015 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 35 increasing their positions, 31 reducing their positions, and 20 closing their positions.
63% more call options, than puts
Call options by funds: $276K | Put options by funds: $169K
13% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 31
12% less funds holding
Funds holding: 102 → 90 (-12)
36% less capital invested
Capital invested by funds: $246M → $156M (-$89.5M)
60% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
+$7.66M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$4.2M |
| 3 |
DM
Deerfield Management
New York
|
+$3.42M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
+$1.93M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$3.76M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$3.51M |
| 3 |
Millennium Management
New York
|
-$2.68M |
| 4 |
Renaissance Technologies
New York
|
-$1.78M |
| 5 |
IHM
Iguana Healthcare Management
New York
|
-$1.58M |
PACB Hedge Fund Activity: Q3 2015 in Review
90 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2015, worth a combined $156M — down 36% from $246M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of PACB and 8 opened new positions — a net loss of 12 holders — while 31 trimmed existing stakes and 35 added.
The largest buyer was Raging Capital Management, opening a new position worth an estimated $7.66M. The largest seller was BlackRock Advisors, cutting an estimated $3.76M.
- 90 institutional investors held Pacific Biosciences (PACB) as of Q3 2015, down from 102 in Q2 2015.
- Funds reported $156M of Pacific Biosciences stock for Q3 2015, down 36% quarter-over-quarter.
- 8 funds opened new Pacific Biosciences positions in Q3 2015 and 20 closed out, a net change of -12 holders.
- The largest Pacific Biosciences buyer in Q3 2015 was Raging Capital Management, an estimated $7.66M added.
- The largest Pacific Biosciences seller in Q3 2015 was BlackRock Advisors, an estimated $3.76M sold.
Based on aggregated 13F filings for Q3 2015.